BJDX Stock — Bluejay Diagnostics Inc

Bluejay Diagnostics Inc (BJDX)

Updated October 16, 2026.

BJDX is a Stock. Total return is -100.0% over the past 4.9 years, 176.0 points behind SPY at 76.0%.

Bluejay Diagnostics is a medical diagnostics company that develops the Symphony platform, an analyzer system paired with single-use cartridges designed to measure key diagnostic biomarkers in blood samples for critical care and other clinical applications. The company is focused on developing tests for conditions including infections, myocardial infarction, and congestive heart failure using its Symphony technology. As an early-stage healthcare company, it does not currently distribute income to shareholders.

BJDX performance versus SPY

Price and return data through 2026-10-16.

Total return is -100.0% over the past 4.9 years, 176.0 points behind SPY at 76.0%. Over the past year its total return — price change plus distributions reinvested — is -93.7%. Its deepest 1-year drawdown was 93.7%.

BJDX key facts

Asset type

Stock

Asset class

Equity

Inception date

11/10/2021

Distribution frequency

None

Last close

$0.74 (as of 2026-10-16)

Market cap

$3,326,464

Average volume

74811.0

Dividend

$0.0975

Beta

0.891

Payout ratio

0.0%

EPS

$-3.58

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BJDX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 93.7%.

Who may consider BJDX — and who may not

It is a weaker fit for investors who need monthly cash flow (BJDX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BJDX

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions